New oral GLP-1 weight-loss medication set to launch in Australia
17 Nov 2026
A new oral medication for weight management and type 2 diabetes is expected to become available in Australia within days, according to pharmaceutical company Eli Lilly.
The medication, called orforglipron and sold under the brand name Foundayo, has been added to the Australian Register of Therapeutic Goods (ARTG). Lilly confirmed on Tuesday that prescriptions would be available in the coming days.
Foundayo is a small-molecule GLP-1 medication taken once daily. It is approved for weight management and type 2 diabetes when used alongside a healthy diet and regular physical activity.
The tablet will come in six strengths, ranging from 0.8 mg to 17.2 mg. Patients will be able to obtain prescriptions through community pharmacies or LillyDirect, the company's own medicine delivery platform.
RACGP President Dr Michael Wright said the new medication would give GPs another treatment option for patients who need help managing their weight or diabetes.
He explained that orforglipron differs from other GLP-1 medicines because it is a small-molecule drug rather than a peptide. This allows it to be absorbed orally without breaking down in the stomach.
Dr Wright said GLP-1 medicines can be effective and well tolerated, but they are not suitable for everyone. He stressed that GPs play an important role in helping patients choose appropriate treatments and monitoring possible side effects or complications.
The approval follows a similar move by pharmaceutical company Novo Nordisk earlier this month. Its oral semaglutide tablet, sold as Wegovy, has also been approved in Australia and is expected to become available for prescribing by the end of 2026.
Unlike Foundayo, the Wegovy tablet must be taken on an empty stomach.
Dr Wright said new treatments were entering the market rapidly, which could make it difficult for patients to understand their options. He highlighted the importance of GPs staying informed and providing patients with reliable advice.
According to the Therapeutic Goods Administration (TGA), Foundayo is approved for adults with obesity who have an initial body mass index (BMI) above 30.
It can also be used by adults with a BMI above 27 who have at least one weight-related health condition, including high blood pressure, abnormal cholesterol levels, prediabetes, type 2 diabetes, obstructive sleep apnoea or cardiovascular disease.
The medication is also approved for treating type 2 diabetes, including cases where metformin is not suitable, and for use alongside other diabetes medicines.
Clinical trial results showed that participants taking orforglipron lost up to 12.4% of their bodyweight over 72 weeks, compared with 0.9% among those taking a placebo. These results were recorded with a higher 36 mg dose.
Research published in the New England Journal of Medicine found that the medication's side effects were similar to those of other GLP-1 medicines. Most were mild to moderate and involved the digestive system.
Between 5.3% and 10.3% of participants taking orforglipron stopped treatment because of adverse events, compared with 2.7% in the placebo group.
Lilly has announced recommended retail prices of $250 for a 30-tablet pack of the three lower strengths and $370 for the two higher strengths. However, the final price may vary between pharmacies.
Dr Wright said the tablet appeared to cost less than injectable GLP-1 medicines. However, it would only be available through private prescriptions.
He also raised concerns about affordability, noting that access to these treatments remains limited for people who cannot afford to pay privately.
Neither of the two newly approved oral GLP-1 medicines has yet been recommended for Pharmaceutical Benefits Scheme (PBS) listing by the Pharmaceutical Benefits Advisory Committee.
New oral GLP-1 weight-loss medication set to launch in Australia
Source: newsGP – RACGP. Information: Therapeutic Goods Administration, Eli Lilly and The New England Journal of Medicine.